Merck KGaA, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, is investing $70 million to expand its R&D facility in Billerica, MA. The new 145,000 sq.-ft. building will offer new lab and collaborative working space to accommodate approximately 400 new and current R&D employees focused on oncology, immuno-oncology and immunology.   When completed in 2021, the building will offer wet labs, office space and a cafeteria for the campus. The building will b...